Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Catalyst Pharmaceuticals announces a settlement with Hetero Labs Ltd. to resolve patent litigation concerning FIRDAPSE (amifampridine). Under the agreement, Hetero will receive a license to market generic FIRDAPSE starting January 2035, pending FDA approval. The settlement ends all pending patent disputes related to FIRDAPSE and aligns with earlier…